AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00602602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00602602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00602602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00602602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00602602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00602602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic biopsy
Study NCT00602602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy
Study NCT00602602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02003924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth once daily
Study NCT02003924 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sugar pill to mimic enzalutamide
Study NCT01854411 — intervention group
Intervention type: OTHER
Intervention: analgesic measure
Description: ibuprofen and ketoprofen measured into breast milk
Study NCT02574156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients will receive insulin. However, the infusion flow will be different according to the group.
Study NCT00505284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, once daily, for 15 weeks (taken orally).
Study NCT03317405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen Hydrochloride
Description: Apply to the skin
Study NCT03317405 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Apply to the skin
Study NCT03317405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03317405 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05083234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizing with SSO
Description: Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.
Study NCT05083234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizing with LV
Description: Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.
Study NCT05083234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The control group was not moisturized.
Description: Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: 25 mg/m2 IV over 1 hour (\<10 kg: 0.83 mg/kg IV over 1 hour)
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: 60 mg/kg IV over 2 hours
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 165 cGy twice daily
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Description: Tacrolimus will start day -3 and will be administered as a continuous IV infusion at a starting dose of 0.03 mg/kg/day. Goal trough levels will be 10-15 ng/mL for the first 14 days post-transplant and then decreased to a goal of 5-10 ng/ml thereafter.
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF 3 gram/day IV/PO for adult patients divided in 2 or 3 doses. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (max 1 gram per dose) every 8 hours beginning day -3.
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Description: 5 ug/kg/d until the absolute neutrophil count (ANC) is >2500/uL for 2 consecutive days
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: BU IV once daily with dose based on Pharmacokinetics (PK) calculator over 3 hours
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 50 mg/m2/day (1.7 mg/kg/day if \< 10 kg) IV over 30 min
Study NCT03674411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGTA 456 Infusion
Description: The target cell dose is >10 x 106 CD34/kg with a maximum TNC 2.7 x 108/kg for children (\<18 years) and 8.1 × 108 cells/kg \[expanded product only\] for adults based on the highest cell dose windows evaluated in prior studies.
Study NCT04036682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-081
Description: CLN-081 tablets
Study NCT03911167 — intervention group
Intervention type: PROCEDURE
Intervention: open, laparoscopic, and robotic
Description: Radical resection of rectal cancer in robotic, laparoscopic, and open approach
Study NCT02612272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: intra-articular ketorolac
Study NCT02612272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: intra-articular betamethasone
Study NCT01723982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barusiban (FE 200440)
Study NCT01723982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT04271852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bio-feedback treatment
Description: 50 patients will treated with phenix u2 and phenix u4 treating equipment。
Study NCT02637245 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03783572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluation
Description: For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score
Study NCT03783572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation and Instrumental evaluation
Description: For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.
Study NCT02694185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caplan IVR
Description: This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
Study NCT03475004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study NCT03475004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study NCT03475004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.
Study NCT03475004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.
Study NCT03475004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
Study NCT03475004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Binimetinib
Description: Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
Study NCT03645122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paired corticospinal-motoneuronal stimulation (PCMS)
Description: Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
Study NCT03645122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will not be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
Study NCT04324827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston Technique
Description: FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
Study NCT04324827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretch exercise
Description: Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
Study NCT01779765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PHGG
Study NCT01779765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT02961894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revolution™ Peripheral Atherectomy System
Description: The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
Study NCT00541658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: 5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
Study NCT00541658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
Study NCT00541658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
Study NCT00505284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007 (2 mg)
Description: Perampanel, 2 mg once daily, for 15 weeks (taken orally).
Study NCT02867436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Study NCT03043417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHC's given the intervention
Description: CHC's NOT given the intervention
Study NCT04353141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: standardized Lung Ultrasound (LUS) examination
Description: 14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score >1; Group C (MODERATE/SEVERE DISEASE)= Score >2 in at least two areas localized bilaterally
Study NCT00505284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007 (4 mg)
Description: Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
Study NCT00505284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007 (6 mg)
Description: Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
Study NCT04411641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Study NCT04411641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Tolebrutinib
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Study NCT03175679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT cells
Description: The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.
Study NCT03175679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
Study NCT03175679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
Study NCT03774446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seliciclib
Description: Drug: Seliciclib
Study NCT00505284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2007 (8 mg)
Description: Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
Study NCT00882154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg Capsule (Sandoz, Austria)
Study NCT00882154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Study NCT02320084 — intervention group
Intervention type: DRUG
Intervention: Nitisinone
Description: Nitisinone according to prescription
Study NCT03548285 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02872883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expectant management
Study NCT02419495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT02872883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal Vaginal examinations (only when necessary)
Study NCT02419495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV
Study NCT02872883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active management
Study NCT03205709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.
Study NCT03205709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Crossword Puzzles
Description: These are intended to mimic crossword puzzles in newspapers.
Study NCT04310462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New e-prescribing interface
Description: The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). Through randomization of clinicians to the new interface, the investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines.
Study NCT02872883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active management
Study NCT02872883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine vaginal examinations
Study NCT02872883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine vaginal examinations
Study NCT03598842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation Meal
Description: Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
Study NCT03598842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Study participants will be given a daily multivitamin to take for 6 months.
Study NCT03598842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-parasitic medications
Description: Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
Study NCT03598842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-parasitic medications
Description: Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
Study NCT01854723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching to NPH insulin
Description: Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
Study NCT01854723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of insulin glargine
Description: Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
Study NCT03143166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Tablet, film coated
Study NCT03969004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous (IV) infusion over 30 minutes